Very nice to see cohort 2 is now wrapped up, with no dose limiting toxicities... that's actually really good news because there was always a chance the dual administration could lead to complications... though it has been done before, never with CLTX CAR-T. Another big box ticked... and now cohort 3 is recruiting, and will accelerated early 2022 once the two new trial sites open up... data will then be generated at 3 sites, vs 1.. so what took 6 months, can now be done in 2!
and if they wait unti first week of June for the ASCO conference... that's near 6 months follow up for all patients in the second cohort... 75% disease control at the lowest dose... what is cohort 2 going to bring ,with double that low dose and dual administration....
goodluck all!
Ann: Successful completion of 2nd dose cohort in CLTX CAR T trial, page-2
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
-0.002(13.0%) |
Mkt cap ! $9.951M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.0¢ | $13.65K | 1.300M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 2625597 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 88904 | 3 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| CHM (ASX) Chart |